Pure Food and Drug Act

The 1906 Pure Food and Drug Act was FDA's founding statute that was created in response to scandals in the meat-packing industry that were widely exposed in Upton Sinclair's book, The Jungle.

From: Clinical and Translational Science , 2009

Regulatory Toxicology

J.W. Kille , in A Comprehensive Guide to Toxicology in Nonclinical Drug Development (Second Edition), 2017

Diethylene Glycol (Elixir Sulfanilamide)

The Pure Food and Drugs Act of 1906 is often considered the first, if vaccines aren't included, of many US laws enacted to protect the public's health from ineffective or dangerous drugs. The FDA didn't exist at that point, and the provisions of this Act were enforced by the Bureau of Chemistry of the Department of Agriculture. As noted above, the Bureau eventually was to become the FDA in 1930. The 1906 Act was specifically intended to prohibit the manufacture, sale, or transportation of adulterated, misbranded, poisonous, or deleterious foods, liquors, drugs, and medicines, and for other purposes, based primarily on what was claimed and specified on its label [18]. If inaccuracies in the label were identified, the manufacturer could be held criminally responsible. But that law had some deficiencies, among which was that it only required that drugs meet standards of strength and purity, and it didn't require the manufacturer of the drug to submit information of any kind to the Bureau before putting it on the market. There was also no requirement to prove the drug was effective in producing the cures that were claimed on its label. It was up to the government to prove that the drug's label was false and misleading regarding claims of curative value. The Sherley Amendment in 1912 addressed this and prohibited false therapeutic claims on the label intended to defraud the consumer, in other words false claims of efficacy. However, while this was a step forward, this Amendment didn't completely solve the problem. As it turned out, establishing that the manufacturer knew ahead of time that the product wouldn't deliver the claimed cure, ie, that the claim was false and there was intent to defraud, proved difficult to establish in a court of law. A further shortcoming was that the ingredients of the medicine didn't have to be displayed anywhere on the container. This was clearly a boon to the manufacturer of the "wonder drug" who wanted to keep the formula secret and mysterious. But this led to many serious problems for the unsuspecting sick individual, including death, as described in the caption for Fig. 19.4. It wasn't until the Gould Amendment of 1913 that the manufacturer was required to display the contents plainly and conspicuously on the outside of the package (Fig. 19.4) [19].

Figure 19.4. A typical "patent medicine" label of the early 1900s, Mrs. Winslow's Soothing Syrup, was marketed for teething and colicky babies. It very likely lived up to its name and was soothing, and it may have been effective for its claimed use. But its label mentioned nothing about what it contained, especially the morphine, nor did it mention the limits of how much should be administered. Many crying infants died as a result of simply being treated for teething discomfort. Congress enacted the 1912 Sherley Amendment to the Pure Food and Drugs Act of 1906, prohibiting labeling of medicines with false therapeutic claims, and specifically forbidding the presence of 11 dangerous ingredients including alcohol, heroine, morphine and cocaine (Munch and Munch, 1956). But it wasn't until 1913 that the Gould Amendment required that the package contents be plainly and conspicuously marked on the outside of the package.

Reproduced from Munch C, Munch Jr C. Notices of Judgment – Numbers 1001 to 5000, Food Drug Law Journal, p. 28. http://www.fda.gov/AboutFDA/WhatWeDo/History/Milestones/ucm128305.htm ; January 1956.

Another glaring omission was the lack of any requirement to provide confirmation, before marketing, that the drug was safe. Once again a tragic event demonstrated clearly that additional controls were needed, and that the Pure Food and Drugs Act needed overhauling. A bill had been introduced in 1933 to make the Act stronger, but there was much political and industry opposition and the bill languished in Congress. In 1937, the S.E. Massengill Co., a medium-size and reasonably well-respected pharmaceutical manufacturer in Tennessee, created a liquid preparation (elixir) of sulfanilamide (a legitimate antibacterial drug). It had already been on the market for a few years in tablet and powder formulations that were successful as a treatment for streptococcal infections, and a liquid formulation (likely intended for sore throats) would fill a marketing niche (Fig. 19.5). The company's chief chemist, Harold Watkins, when trying to make an aqueous solution, found that sulfanilamide was not very soluble in water, but was soluble in diethylene glycol (DEG), a sweet-tasting solvent (a commonly known solvent used in other commercial products including brake fluid and automobile antifreeze). So, with the addition of some raspberry flavoring, the DEG/Elixir Sulfanilamide was ready to go to market. But Watkins didn't test the formulation for safety in animals, nor was he required to do so by the Pure Food and Drugs Act, before distributing it to Massengill's salesmen. It was already known and published in the scientific literature at that time that DEG was toxic, but Watkins was either unaware of this, or economics played a part since DEG was a cheaper ingredient than other solvents available and profit margins would be improved. As it turned out, DEG was dreadfully toxic to the kidneys. Even though Elixir Sufanilamide was legally marketed, it caused extremely painful deaths by kidney failure of 107 people, many of them children, often within the remarkably short time of 1 to 11   days after ingestion [18]. But since the current Act didn't require the manufacturer to establish the safety of the product before marketing it, getting Elixir Sulfanilamide off the market was difficult. The government, however, was cleverly able to establish that the term "elixir" as then used meant a solution containing alcohol. Since DEG was the solvent in Elixir Sulfanilamide, and it contained no alcohol, this elixir was therefore misbranded and not in compliance with the law. In the wake of these deaths, knowing he was responsible for the decision to use DEG in the elixir, Harold Watkins committed suicide. A positive outcome of this episode was that it drove the passage and enactment of the Federal Food, Drug, and Cosmetic Act (FD&C) of 1938, which superseded the Pure Food and Drugs Act. This latest Act with its amendments was the substantial revision that was needed, and is the basis for the food, drug, and cosmetic laws that are in effect today in the United States. The FD&C Act of 1938 completely overhauled the public health system, and was the first to demand premarket evidence of safety for new drugs. This essentially shifted the burden of proof of safety and efficacy from the FDA to the manufacturer.

Figure 19.5. Elixir Sulfanilamide bottles—S.E. Massengill Co., c.1937–1938.

Reproduced from http://www.fda.gov/AboutFDA/WhatWeDo/History/ThisWeek/ucm117880.htm?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=elixir%20sulfanilamide&utm_content=4 .

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9780128036204000190

Technical considerations for the implementation of food safety and quality systems in developing countries

André Gordon , ... Brian Bedard , in Food Safety and Quality Systems in Developing Countries, 2020

Background

Since the passage of the Pure Food and Drug Act of 1906 and subsequent revisions of the Federal Food, Drug and Cosmetic Act, the combined efforts of the government and the food industry have produced a set of standards and practices to improve food safety. These efforts include the adoption of Good Manufacturing Standards which provided the foundation to further food safety programs including current Good Manufacturing Practices, Low-Acid Canned Foods, Hazard Analysis Critical Control Points (HACCP), and more recently Preventive Controls regulations.

HACCP is an important preventive control-management system and can be integrated into any operation. The HACCP concept was first applied to food production during efforts to supply safe food for the U.S. space program in early 1960s, and through recommendations put forth by the National Academy of Sciences and the U.S seafood industry, the U.S Food and Drug Administration (FDA) finalized the Seafood HACCP regulation and USDA published their Pathogen Reduction HACCP regulation in the July 1996. Those regulations were followed by FDA's Juice HACCP regulation in January 2001. By then, HACCP principles, programs and regulations had been endorsed world-wide and provided some assurance of safe food products.

From a public health perspective, however, foodborne illness continued to place a significant burden on the public as the U.S. food supply became more complex, more foods were being imported and new hazards were found in food that were not previously seen. As a result, the FDA Food Safety Modernization Act (FSMA), the most sweeping reform of U.S. food safety laws in more than 70 years, was signed into law in January of 2011. The law provided FDA new enforcement authorities, mandated new risk-based food safety standards and provided new tools to hold imported foods to the same standards as domestic foods.

Among those tools were increased inspections of foreign producers across multiple continents, the experience of Caribbean exporters in the early years of FSMA being discussed by Gordon (2013). This chapter will discuss one of the seven mandated regulations under FSMA, the Current Good Manufacturing Practice, Hazard Analysis, and Risk based Preventive Controls for Human Food regulation (hereafter referred to as the cGMP/Preventive Controls for Human Food regulation). Among the other regulations that have impacted exporters are the Foreign Supplier Verification Program (FSVP) which is specific to U.S. importers and the Produce Safety Rule were both discussed in overview in Saltsman and Gordon (2015). Other important rules that impact exports to the US include the rule on the Sanitary Transportation of Human and Animal Food (Sanitary Transportation) Rule, issued in April 2022 and Mitigation Strategies to Protect Food Against Intentional Adulteration (Food Defense Rule) issued in May 2016. Of the seven (7) rules that are an important part of the FSMA, the most important and most far reaching, impacting many aspects of the operation of the food industry and bringing all areas of the industry not governed by other specific regulations under the FDA's jurisdiction. Being among the more recent of comprehensive international food legislations, it has benefitted from not only domestic considerations, but also being able to be structured to assure equivalence with other legislation in major global economies. It will therefore be used in this volume as the point of reference for food safety regulations, the United States being the major market globally for food imports.

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9780128142721000012

Development of Food Legislation Around the World1

In Ensuring Global Food Safety, 2010

2.7.4.4 Evolution of the Food Statutes

Not long after passage of the Pure Food and Drug Act, legislative battles began to expand and strengthen the law. For example, leaders in the food industry called for more stringent product quality standards to create a level playing field. Consumers wanted stronger safety standards and fair dealing. However, major revision of the 1906 Act stalled until a precipitous tragedy occurred. The agonizing deaths of more than 100 children from sulfanilamide spurred the passage of the Federal Food, Drug, and Cosmetic Act of 1938.

This pattern for major revision of the national food law repeats itself. A tragedy alone is not enough. Concerns of a few interested parties are not enough. Typically, scientists, the food industry, and the public must all be interested in addressing the issue of the day.

The food laws continued to evolve based upon the concerns and issues of the times. In the 1950s, concerns over synthetic food additives, pesticides, and cancer were high. Consequently, in 1958, the Food Additives Amendment was enacted, requiring the evaluation of food additives to establish safety. The Delaney Clause forbade the use of any substance in food that was found to cause cancer in laboratory animals.

In 1920, the Canadian Adulteration Act was repealed and replaced with the Food and Drug Act of 1920. While the predecessor acts were significantly influenced by British law, this new statute looked more like the US Pure Food and Drug Act of 1906 (Gnirss, 2008). The Canadian Food and Drug Act of 1920 was revised in 1952-53 to cover cosmetics and therapeutic devices and to increase the regulation over labeling, packaging, and advertising (Blakney, 2009).

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9780123748454000023

Food safety: marketing trends intended for consumer awareness and partnership

Palma Ann Marone , in Developing New Functional Food and Nutraceutical Products, 2017

5.3.1 Recent policy initiatives directing food safety awareness

Since the passage of the 1906 Pure Food and Drugs Act, the regulatory functions of the FDA (1930) through the Federal Food, Drug, and Cosmetic Act (1938, FFDCA) have undergone transformation and enhancement in the directive to improve food safety. These changes culminated in January 2011 in the Food Safety Modernization Act that provided the FDA with a sweeping mandate over food manufacturers, foreign and domestic, from adverse event response to prevention. The most recent directive within this law (September 2015) is the final rule for current good manufacturing practice, hazard analysis, and risk-based preventive controls for human and animal foods (http://www.fda.gov/Food/GuidanceRegulation/FSMA/ucm334115.htm). In response to calls from consumer advocacy groups, local regulatory bodies, and industry, the FDA has mandated preventative critical control points for minimum standards for both the safe production and harvesting of produce, and across the food manufacturing and processing supply chain. With the final rule recently passed (Aug. 2015) and compliance dates expected to begin in Sep. 2016, manufacturers, through comprehensive documentation of process, become the initial and vital responsible party in the supply of safe food.

In an effort to better assist consumers toward making and maintaining healthy food choices and to avoid those ingredients with potentially adverse effects in allergic individuals, the FDA has proposed to update the 20-year-old Nutrition Facts label found on food packaging (http://www.fda.gov/Food/GuidanceRegulation/GuidanceDocumentsRegulatoryInformation/LabelingNutrition/ucm385663.htm). A comprehensive review of the proposed changes can be found in Marone and Birkenbach (2016). To summarize here briefly, the changes include updates for serving size requirements to reflect the larger portion sizes people eat today, prominently displaying serving sizes and calories, adding a declaration for "added sugars," and indication for the type of fat (saturated, trans) over the amount. Public comment on the proposed changes has just concluded with formal label changes expected within 2 years of ratification. In the most recent amendment to strengthen the Food Labeling Modernization Act (FLMA, 2013, https://www.opencongress.org/bill/hr3147-113/text), a new provision adds sesame to the list of the major food allergens and the requirements for submission of food label information with imported foods. The food ingredient label is meant to empower the consumer with the basic information to formulate his/her own position in food selection with as little influence from the manufacturer as possible. In a recent Supreme Court decision (POM Wonderful LLC v. FTC, 13-1060, U.S. Court of Appeals, District of Columbia (Washington)) ruling against false advertising, the original FFDCA mislabeling law was upheld to ensure consumer protection against foods or beverages having been adulterated, knowingly contaminated, misbranded, or carrying false claims regarding health benefits (Zajac, 2015). This ruling demonstrates the seriousness with which regulatory authorities regard the need for accuracy in advertising in order to prevent dissemination of objectively false information to consumers.

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9780128027806000055

Food additives

Michael Zeece , in Introduction to the Chemistry of Food, 2020

Review questions

1.

What are the important outcomes of the Pure Food and Drug Act of 1906?

2.

Why is adding water to milk considered to be an act of adulteration?

3.

Describe the term GRAS and its importance to food additives.

4.

Give one example each of an acid and a base used as food additive.

5.

What is "Chemical Leavening"? Give an example of how it works in a food system.

6.

What are the major reasons for adding salt to food?

7.

What is the function of acetic, propionic, and sorbic acids in food?

8.

Give two reasons for adding nitrite to processed meats.

9.

What is the health concern for nitrite in bacon?

10.

Why is sulfite used in food systems? Give two examples.

11.

What is a chelator and why are they added to foods?

12.

Why is ascorbic acid added to food systems? Give two examples of it use.

13.

Define the term hydrocolloid and give two examples of their use as food additives.

14.

What is the importance of gels in processed foods? Give two examples of substances used to form gels in food systems.

15.

What is rum caviar and how is it made?

16.

Give two examples of emulsifiers and describe their use in food systems.

17.

What is a fat replacer? Give an example.

18.

Give an example of enzymes used as a food additives.

19.

Define the terms toxin and toxicant. Give an example of each.

20.

Give an example of a toxicant that results from the Maillard reaction.

21.

What is trypsin inhibitor and where is it found?

22.

Name 2 sources of trypsin inhibitor.

23.

What is the difference between direct and indirect food additives?

24.

What are mycotoxins? Give two examples.

25.

Name three toxic elements and foods they might be found in.

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9780128094341000074

Regulatory Environment

Christine Nguyen , ... Hylton V. Joffe , in Clinical and Translational Science (Second Edition), 2017

Legal Authority

The FDA celebrated its centennial in 2006. The 1906 Pure Food and Drug Act was FDA's founding statute that was created in response to scandals in the meat-packing industry that were widely exposed in Upton Sinclair's book, The Jungle. Sinclair described appalling situations such as dead rats shoved into sausage grinders and bribery of inspectors, who permitted diseased cows to be slaughtered for beef. The 1906 law provided the federal government with authority to remove dangerous or falsely labeled foods and drugs from the market but did not limit claims made by manufacturers and did not require approval or premarketing testing of these products.

FDA's modern legal authority began with the 1938 Federal Food, Drug, and Cosmetic Act, spurred by the elixir of sulfanilamide tragedy. Sulfanilamide, a bitter-tasting antimicrobial used for the treatment of streptococcal infections, was dissolved in a sweet-tasting liquid to appeal to pediatric patients. The manufacturer did not perform toxicity testing on this new solvent, which contained ethylene glycol (antifreeze) and caused more than 100 deaths, including many children. The 1938 Act required manufacturers to establish safety prior to marketing of new drugs (these requirements for safety are identical to those in current law) and required submission of a new drug application (NDA) to the FDA prior to marketing. The drugs would be approved if the FDA did not object within 180   days after receiving the marketing application.

FDA's drug authority was further strengthened in 1962 with the passage of the Kefauver–Harris Drug Amendments (http://www.fda.gov/oc/history/default.htm), which was spurred by the thalidomide tragedy. Thalidomide was marketed as a sleep-aid to pregnant women outside the United States and caused major birth defects (mainly phocomelia) in thousands of children. Thalidomide was never marketed in the United States, thanks to FDA reviewer Dr. Frances Kelsey, but some exposure did occur when it proved impossible to find all of the drug product that had been distributed for investigational use. The 1962 amendments required that manufacturers of new drugs establish efficacy in addition to safety, which was a response to hearings prior to Kefauver–Harris that established the poor quality of studies that had been performed to support the effectiveness of drugs and the absurd labeling that had resulted from these studies. The amendments also required that the FDA give positive approval before a new drug could be marketed, a major change in the review/approval dynamics. In addition, the amendments required that the Secretary of DHHS promulgate regulations (e.g., informed consent) to cover drugs for investigational uses. The amendments also established Good Manufacturing Practices (GMP), which require high standards during the manufacturing process of drugs (e.g., sanitation, qualified personnel, appropriate equipment, and validation and documentation of the manufacturing process).

To determine whether there is substantial evidence of effectiveness, the regulations require reports of "adequate and well-controlled investigations" (21 CFR 314.126). The use of the plural form of the word "investigation" is interpreted, in accordance with legislative history, as a requirement for at least two well-controlled trials to support efficacy (the 1997 Food and Drug Administration Modernization Act permits demonstration of efficacy based on a single pivotal study, where appropriate and when agreed to by the FDA). The process of independent substantiation with at least two well-controlled clinical trials is important, because a positive finding from one trial is more likely to represent a chance finding and the single trial may have undetected biases. The trials do not need to be identical in design (e.g., for the second study, the drug could be evaluated in a different phase of the disease or in a different patient population), but each trial must include a clear statement of the study objectives; a valid comparison with a control; an adequate number of research subjects with the condition of interest; a design that minimizes bias and assures comparability of the treatment groups; objective, well-defined, and prespecified methods for assessing response to treatment; and appropriate, predefined analyses (21 CFR 314.126; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072008.pdf). The law does not require a new drug to be better than, or even as good as, an already approved drug (although such comparisons may be informative), but the effect of the new drug must be clinically meaningful (Warner-Lambert v. Heckler, 1986).

The 1962 amendments also called upon the FDA to evaluate the effectiveness of all drugs approved solely on the grounds of safety between 1938 and 1962. To accomplish this mandate, the FDA contracted with the National Academy of Sciences/National Research Council to carry out the Drug Efficacy Study. Implementation of this study is called DESI (Drug Efficacy Study Implementation) (http://www.fda.gov/oc/history/default.htm). Over 3000 DESI drugs have been reviewed. Approximately one-third were found to be ineffective and have subsequently been withdrawn from the market.

In 1992, Congress passed the Prescription Drug User Fee Act (PDUFA), which has subsequently been reauthorized every five years. Under PDUFA, sponsors (individuals or organizations who are responsible for the research studies) pay user fees to the FDA when certain applications are submitted to the FDA for review. These fees, together with federally appropriated funds, support the drug review process and have been used to hire additional review and support staff, upgrade data systems, and improve procedures that make reviews more rigorous, consistent, and predictable. In exchange for the user fees, the FDA has agreed to meet performance goals (see later discussion for details) during drug development and review, ensuring timely review of drug applications, while preserving the integrity of the review process, with the goal of assuring that safe and effective drugs are made available to the public in a timely manner. PDUFA has established expectations of FDA review timelines for marketing applications, developed processes for interactions with sponsors during all phases of drug development, and implemented programs to ensure drug development in unmet medical conditions (e.g., pediatric drug development). Importantly, PDUFA performance goals do not apply to approval times (i.e., the FDA can require as many review cycles as it deems necessary to ensure an adequate demonstration of efficacy and safety prior to considering approval of the medical product).

In 1997, Congress passed the FDA Modernization Act (FDAMA), which established the Fast Track process, permitted evidence of efficacy based on a single clinical trial (where appropriate), and reauthorized PDUFA. The Fast Track process was designed to facilitate the development and expedited review of drugs that address unmet needs for the treatment of serious or life-threatening conditions. The Fast Track process includes an existing regulation, "Subpart H" (also known as accelerated approval), which allows certain products meeting the above criteria to be approved based on a surrogate endpoint that is not as well established as regularly used surrogates, such as blood pressure, but is reasonably likely to predict clinical benefit. An approval based on a positive response in the surrogate endpoint requires postapproval studies to confirm clinical benefit. The FDA can withdraw approval if the sponsor fails to satisfy the postapproval requirement, if safety issues arise, or if no benefit is confirmed.

The 2007 Food and Drug Administration Amendments Act (FDAAA) reauthorized PDUFA and also provided the FDA with important new regulatory authorities that significantly enhanced FDA's authority to oversee drug safety after approval. Some important FDAAA provisions included the authority to require Risk Evaluation and Mitigation Strategies (REMS) and to require certain studies or trials be conducted to address specific safety concerns. FDAAA also provided FDA with a new authority to require labeling changes for important safety information during the postmarketing period. Manufacturers not complying with these new requirements may face civil penalties and fines. These important authorities are discussed in more detail later in the chapter.

In 2012, Congress passed the Food and Drug Administration Safety and Innovation Act (FDASIA). FDASIA reauthorized PDUFA and also created a novel expedited drug development program called "breakthrough therapy" designation. This designation commits the FDA to help expedite the development and review of new drugs when there is preliminary clinical evidence that the drug may offer substantial improvement over available therapies for patients with serious or life-threatening illnesses. FDASIA also established the Generic Drug User Fee Amendments (GDUFA), which for the first time established user fees that drug companies must pay to support the review of generic drugs. Funding through GDUFA will provide the FDA with the necessary resources for more predictable and timely review of generic drug applications.

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9780128021019000235

Regulatory Approval

Tom Brody Ph.D. , in Clinical Trials (Second Edition), 2016

I Origins of the Federal Food, Drug and Cosmetic Act and Its Amendments

This outlines the history of the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the International Conference on Harmonisation (ICH). Also described is the organization and content of various regulatory submissions, as well as various milestones in the process of obtaining regulatory approval.

Federal regulation of drugs began with the Pure Food and Drug Act of 1906. That law made the manufacture of an adulterated or misbranded drug a misdemeanor, carrying a punishment not to exceed a $200 fine and/or one year in prison for the first conviction.

Harvey W. Wiley is known as the "Father of the Pure Food and Drugs Act of 1906." Dr Wiley received his medical degree at Indiana Medical College in 1871, then did laboratory work on sugar chemistry, with the aid of a polariscope, in the Imperial Food Laboratory in Germany (1). Then he returned to the mid-west in the United States, where he studied sorghum and sugars at Purdue University, and in 1883 became a chemist at the US Department of Agriculture. Dr Wiley created the "Poison Squad" in 1902, which was a group of 20 healthy men who were chosen to eat foods containing suspected poisons that were dyes or preservatives. He determined that borax, a food preservative at the time, was poisonous to man. Dr Wiley became a crusader for national food and drug regulation, and was FDA Commissioner from 1907 to 1912.

The Pure Food and Drug Act of 1906 did not require government clearance for new drugs, and companies were still permitted to market new drugs without first proving their safety or effectiveness (2).

By the mid-1930s, dissatisfaction with the 1906 law led to efforts to strengthen this law.

Senator Royal S. Copeland, a physician and former New York City health commissioner, worked to reform the old statute, and argued (3):

A law which permits the continued manufacture and sale of utterly worthless remedies for cancer, tuberculosis, diabetes, and other maladies considered incurable by such means, is certainly defective. Because their manufacturers cannot be shown to know that their products are worthless creates a legal situation which is unbearable. That actually poisonous cosmetics and injurious slenderizing compounds can be distributed without interference from the Federal Government is positively indecent.

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9780128042175000333

The legal basis for food safety regulation in the USA and EU

Caroline Smith DeWaal , ... David Plunkett , in Foodborne Infections and Intoxications (Fifth Edition), 2021

The Pure Food and Drugs Act

The Food and Drugs Act of 1906 (also called the Pure Food and Drugs Act) [7] covered food, drink, confectionery, and condiments used by man or other animals, "whether simple, mixed, or compound." The law prohibited the addition of any ingredients that would substitute for the food, conceal damage, pose a health hazard, or constitute a filthy or decomposed substance. It defined for the first time in a federal statute the terms "misbranding" and "adulteration," and gave the federal government the authority to seize adulterated or misbranded foods and punish violators with fines of up to $500 and/or imprisonment of up to 1 year for the first offense. The FDA could sample imported foods for adulteration, misbranding, or health hazards. The Act transformed the Division of Chemistry from a scientific bureau to a regulatory agency.

Although it was a good start and accomplished much, from the beginning the Food and Drugs Act had some very large flaws that made it almost impossible to prove adulteration of a food. For example, without knowing how much strawberry was supposed to be in strawberry jam, the FDA could not prove that a product containing almost no strawberries was not strawberry jam. Furthermore, the Act required the government to prove that alleged offenders of the law intended to deceive or poison consumers with their product. When brought to court, defendants pleaded ignorance of the results of their actions. While the law prohibited false labeling, producers did not have to list ingredients in their products [4]. Nevertheless, the Act endured as the major law regulating the food supply until the early 1930s when the movement for reform started anew.

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9780128195192000050